**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 63078

**Manuscript Type:** MINIREVIEWS

**Diabetes and gut microbiota**

Xi Y *et al*. Diabetes and gut microbiota

Yue Xi, Peng-Fei Xu

**Yue Xi, Peng-Fei Xu,** Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA

**Peng-Fei Xu,** Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China

**Author contributions:** Xu PF designed the framework and supervised the preparation; Xi Y and Xu PF wrote the manuscript and prepared the figures, both authors read and approve the final manuscript.

**Supported by** Open Fund of Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, No. 201705.

**Corresponding author: Peng-Fei Xu, PhD, Academic Research, Postdoctoral Fellow, Research Associate,** Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, 323 Salk Pavilion, 335 Sutherland Drive, Pittsburgh, PA 15261, United States. [pex9@pitt.edu](mailto:pex9@pitt.edu) or dyxufei@sina.com

**Received:** January 24, 2021

**Revised:** April 20, 2021

**Accepted:** August 5, 2021

**Published online:**

**ABSTRACT**

The prevalence of diabetes has increased rapidly throughout the world in recent years. Currently, ~463 million people are living with diabetes, and the number has tripled over the last two decades. Here, we describe the global epidemiology of diabetes in 2019 and forecast the trends to 2030 and 2045 in China, India, USA, and the globally. The gut microbiota plays a major role in metabolic diseases, especially diabetes. In this review, we describe the interaction between diabetes and gut microbiota in three aspects: probiotics, antidiabetic medication, and diet. Recent findings indicate that probiotics, antidiabetic medications, or dietary interventions treat diabetes by shifting the gut microbiome, particularly by raising beneficial bacteria and reducing harmful bacteria. We conclude that targeting the gut microbiota is becoming a novel therapeutic strategy for diabetes.

**Key Words:** Diabetes; Gut microbiota; Epidemiology; Probiotics; Anti-diabetic medication; Diet

Xi Y, Xu PF. Diabetes and gut microbiota. *World J Diabetes* 2021; In press

**Core Tip:** The current review describes the global epidemiology of diabetes in 2019 and forecasted the trends to 2030 and 2045 in China, India, USA, and globally. This review also summarizes the interaction between diabetes and the gut microbiota in three aspects: probiotics, antidiabetic medications, and diet.

**INTRODUCTION**

The global prevalence of diabetes has grown rapidly in recent decades. Diabetes is becoming a serious global health threat, and is one of the top 10 leading causes of death among adults[1]. The etiology and progression of diabetes are commonly driven by genetic and environmental factors. The International Diabetes Federation (IDF) estimates that in 2019 there were 463 million cases of diabetes mellitus worldwide and ~4.2 million adults died from diabetes and its complications[2]. It is estimated that ~700 million adults will be diagnosed with diabetes by 2045. Diabetes mellitus is a group of metabolic diseases that cause high blood glucose, and primarily includes type 2 diabetes (T2D), type 1 diabetes, prediabetes, and gestational diabetes. T2D isthe most common type of diabetes and represents ~90% of all diabetes patients worldwide[3].

The gut microbiota is a collective term for the intestinal microbial community, which plays a crucial role in maintaining health and disease pathogenesis. Recently, the gut microbiome has become an emerging research area for diabetes management, as gut dysbiosis directly or indirectly participates in diabetes by affecting host intestinal barrier functions and metabolic homeostasis[4]. Animal and human studies have identified related differences in the composition of the gut microbiota in patients with diabetes[5]. In this review, we describe global trends in diabetes in 2019, predict the trends to 2030 and 2045, and summarize the latest findingsregarding the gut microbiota in diabetes.

**EPIDEMIOLOGY OF DIABETES**

Diabetes is one of the fastest growingglobal health challenges in the last 40 years, with the number of adults living with diabetes rising from 108 million in 1980 to 463.0 million (368.7–600.6 million) in 2019. This number is projected to reach 578.4 million (456.5–747.6 million) in 2030 and 700.2 million (540.7–904.6 million) in 2045.The global prevalence of adult diabetes increased from 4.7% in 1980 to 8.3% (6.2%–11.8%) in 2019, and is projected to reach 9.2% (6.8%–12.9%) in 2030 and 9.6% (7.1%–13.4%) in 2045[1]. Although the common long-term complications in diabetic patients develop gradually, they could be disabling or even life-threatening over time[6].Diabetes is a major cause of many diseases, such as eye damage, kidney failure, heart and blood vessel disease,neuropathy, Alzheimer’s disease, and lower limb amputation.Global diabetes-related health spending continues to grow rapidly as well. It was 760 billion US dollars in 2019, ~10% of total global health spending, and is expected to reach 825 billion US dollars in 2030 and 845 billion in 2045[7].

China and India were the two countries with the highest number of adult diabetic patients in 2019 and are projected to remain so in 2030 and 2045, due to the demographic and socioeconomic status factors. The IDFDiabetes Atlas (9th edition 2019) estimated thenumber of people with diabetes in China, India, USA, and the world in 2019, and projected that by 2030 and 2045 (Figure 1),the number of adults living with diabetes in China will increase from 116.4 million (108.6–145.7 million) in 2019 to 140.5 million (130.3–172.3 million) in 2030, and 147.2 million (134.7–176.2 million) in 2045.In India, the number of diabetes cases is projected to grow from 77.0 million (62.4–96.4 million) in 2019 to 101.0 million (81.6–125.6 million) in 2030, and 134.2 million (108.5–165.7 million) in 2045. The number of adult diabetes cases in the USA will increase from 31.0 million (26.7–35.8 million) in 2019, to a projected 34.4 million (29.7–39.8 million) in 2030 and 36.0 million (31.0–41.6 million) in 2045.Over the last 40 years, the number of people with diabetes has quadrupled throughout the world. The prevalence of diabetes will increase more rapidly in low-income than in high-income countries in the near future[1]. Unmet medical needs related to diabetes are a growing global public health problem.

**INTERACTION BETWEEN DIABETES AND GUT MICROBIOTA**

Observational findings from recent epidemiological, physiological and metabolomic studies, complemented by cellular and animal experiments and clinical trials, it appears that microbial communities may contribute to the pathogenesis of a variety of common metabolic disorders, including obesity and diabetes, and their complications[3,8].Although accumulative evidence suggests thatthegut microbiota is a factor influencing diabetes, the underlying mechanisms remain unclear.Due to the crosstalk between the gut microbiota and host homeostasis, the gut microbiome is thought to play a crucial role in obesity and associated metabolic dysfunction[9,10]. Thegut microbiome has been shown to affect host metabolism, food consumption, body weight, and glucose and lipid homeostasis. Gut dysbiosis or altered microbiota composition has been detected in obesity and diabetes in human and murine models[11]. Treatment with probiotics, antidiabetic medications, or dietary interventions can orchestrate the gutmicrobiome, leading to increased probiotic bacteria and decreased harmful bacteria, and these changes subsequently contribute to bodyweight loss, suppression of inflammation, and maintenance of glucose homeostasis in the host[12]. Targeting the gut microbiota is developing into a possible therapeutic strategy for diabetes.

***Probiotics***

Probiotics are living microorganisms that provide health benefits to their host, particularly the digestive system.Probiotics, such as*Akkermansia*, *Bacteroides*, *Bifidobacterium* and *Lactobacillus*, are currently suggested as novel and potential biotherapeutics in the prevention and management of diabetes[13,14]. Oxidative stress is a key player in the development of diabetes and diabetes-related complications[15]. Supplementation with probiotics and also synbiotics could be beneficial for patients diagnosed with diabetes also because these products lower oxidative stress levels[16,17]. Cumulative studies have proven the efficacy of probiotics in the treatment of diabetes by decreasing fasting glucose and insulin levels in animal models and clinical trials[18].

*Akkermansia muciniphila* is a species of mucin-degrading bacteria recently found in the human gut, and its abundance has been reported to be inversely correlated with obesity, T2D and inflammation[19-22].Administrationof *A. muciniphila* protected against high fat diet (HFD)-induced obesity and insulin resistance by suppressing inflammation and improving gut barrier function. In addition,a purified protein in the outer membrane of *A. muciniphila* called Amuc-1100 could improve metabolic syndrome in obese and diabetic mice through the Toll-like receptor 2 signaling pathway[23]. In humanclinical trials, supplementation with *A. muciniphila* compared to the placebo improved insulin sensitivity,reduced insulinemiaand plasma total cholesterol, and decreased body weightin overweight/obese insulin-resistant volunteers[24]. In our recent studies, we found that melatonin, a probiotic agent, partially improved insulin resistance by increasing the abundance of *A. muciniphila* in HFD-fed mice[25]. *A. muciniphila* is considered a promising probiotic to improve diabetes and obesity-associated metabolic disorders.

*Bacteroides* is a common genus associated with the risk of T2D in patients. However, the role of *Bacteroides* in diabetes is controversial. Some studies have shown that the abundance of *Bacteroides* is inversely associated with diabetes risk[26-30], while others have reported a positive association in different species[31-33]. This inconsistency may be explained by the underlying feedback mechanism of the gut microbiome at different stages of the disease or in different animal models. The ratio of Bacteroidetes to Firmicutes, previously identified as a marker for metabolic diseases, does not seem to be consistently associated with diabetes risk[14].In animal studies, treatment with *Bacteroides acidifaciens* and *Bacteroides* *uniformis* prevents obesity and improves insulin susceptibility in diabetic mice[34,35].These studies suggest that *Bacteroides* may have a beneficial effect on diabetes.

*Bifidobacterium*,also known as *Lactobacillus bifidus*, is frequently reported in T2D protection studies. *Bifidobacterium* strains are crucial probiotics in thedairy industry, due to their unique function of fermenting carbohydrates *via* the fructose-6-phosphate phosphoketolase pathway[36]. Numerous studies have shown that *Bifidobacterium* has beneficial effects on glucose tolerance in individuals with T2D anddiabetic murine models[37-39].Oral administration of *Bifidobacterium* decreasesblood glucose concentration and glycosylated hemoglobin levels, and improves lipid profiles, insulin resistance, and antioxidant indexes, through insulin receptor substrate/phosphoinositide 3-kinase/protein kinase B and kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling pathway in murine diabetic models[40]. *Bifidobacterium* may be a promising probiotic to treat diabetes.

*Lactobacillus* is the most commonly used probiotic in industry tocontrol food fermentation, such as yogurt, cheese, wine, and other fermented foods.Studies of the composition of gut microbiota showed some species in this genus were increased in T2D patients, such as *Lactobacillus acidophilus*, *Lactobacillus gasseri* and *Lactobacillus salivarius,* whereas *Lactobacillus amylovorus* was decreased in patients with diabetes[41-43]. Oral supplementation of *Lactobacillus*, such as *Lactobacillus casei*, *Lactobacillus curvatus*,*L. gasseri*, *Lactobacillus paracasei*, *Lactobacillus plantarum*,*Lactobacillus reuteri*, *Lactobacillus rhamnosus* and *Lactobacillus sakei*, exhibited beneficial effects in diabetic mice and individuals with diabetes[44-54]. The antidiabetic mechanism of *Lactobacillus* by inhibitingendotoxin secretion and activating G-protein-coupled receptor 43 pathway has been reported[55]. The combination of*Lactobacillus* and *Bifidobacterium* is widely used in clinical practice to synergistically maintain a healthy digestive tract. Growing evidence supports that probiotics are a safe and effective treatment strategy under certain clinical conditions of diabetes.

***Diet***

Diet is an essential regulator of the gut microbiome[56]. Interactions between diet and gut microbiota have been reported to affect obesity, insulin resistance, and the chronic inflammatory response of the host[57]. Here, we mainly summarize the roles of diet in the gut microbiome and diabetes.

Diet composition is vital in diabetes development. Diabetes was considered a disease of the rich, because of its high prevalence among the rich who access food more easily, including flour, sugar, fat and meat[58]. It has been shown that diets with high levels of sugar, fat and cholesterol increase the risk of diabetes. These diets cause gut dysbiosisand damage the intestinal mucosal barrier that facilitates the development of diabetes[59,60].High-fiber diet is a well-known healthy diet with various benefits, such as improving bowel movements, lowering cholesterol,achieving a healthy weight, and controlling blood sugar levels. Dietary fibers consist of cellulose, resistant starch and dextrin, inulin, lignin, pectin, β-glucan, and oligosaccharides. They are abundant in whole-grain bread and cereals, legumes, rice, vegetables andfruits, and cannot be completely digested or absorbed by the human digestive system[61,62].Dietary fibers play an essential role in maintaining the gut microbiota and gut health, as they can becatalyzed and fermented by certain gut microbes and produce beneficial metabolites, such as short-chain fatty acids (SCFAs)[63].In the gut, ~95% of SCFAs are acetate (C2), propionate(C3), and butyrate (C4)[64]. Studies have shown that acetate is mainly produced by bacteria, such as *A. muciniphila*, *Bifidobacterium* spp., *Bacteroides* spp., *Lactobacillus* spp., *Prevotella* spp., *Ruminococcus* spp. and *Streptococcus* spp. through the acetyl-coenzyme A pathway[65,66]. Propionate is mainly produced by *Bacteroides* spp., *Coprococcus catus*, *Dialister* spp., *Megasphaera elsdenii*, *Phascolarctobacterium succinatutens*, *Roseburia inulinivorans*, *Ruminococcus obeum*, *Salmonella* spp. and *Veillonella* spp. through three known pathways, *i.e.*, succinate pathway, acrylate pathway, and propanediol pathway[66,67]. Butyrate is produced primarily in *Anaerostipes caccae*, *Clostridium leptum*, *Coprococcus catus*, *Coprococcus eutactus*, *Eubacterium hallii*, *Eubacterium rectale*, *Faecalibacterium prausnitzii*, and *Roseburia* spp., by enzymatic catalysis,such as butyryl-CoA dehydrogenase,butyryl-CoA transferase, and phosphotransbutyrylase or butyrate kinase[66,68]. SCFAs are critical modulators in pathophysiological events of diabetes. They act directly as histone deacetylase inhibitors and increase protective glucagon-like peptide-1 secretion[69], which decreases blood glucose levels, improves insulin resistance, and suppresses inflammation. Our previous studies have shown that dietary lipid adsorbent montmorillonite regulates intestinal absorption and gut microbiota, such as increasing SCFAs-producing *Blautia* bacteria, thereby preventing obesity and insulin resistance in HFD-fed murine models[70,71]. However, dietary effects on the shift of gut microbiota appear to be temporary[72]. Habitual diets, which have a longer lasting influence on the gut microbiome, may be a viable strategy.

***Antidiabetic medications***

Metformin is an oral antidiabetic medication. It has beenused in the treatment of T2D for >60 years due to its distinct effects on decreasing glucose production and increasing insulin sensitivity, as well as its safety profile.Metformin originates from *Galega officinalis*, a natural source of galegine[73]. Traditionally, activation of the AMP-activated protein kinase signaling pathway in the liver is thought to be the mechanism of its antidiabetic effects[74].Recent findings indicate that metformin also orchestrates gut microbiome in mice and humans[43]. Sun *et al*[33] reported that metformin improves hyperglycemia through the gut microbiota-bile acid-intestinal farnesoid X receptor (FXR) axis in T2D patients.FXR is an important target in regulating glucose and lipid homeostasis. Metformin reduces the level of *Bacteroides fragilis* in the gut, leading to an increase in the FXR antagonist, glycoursodeoxycholic acid. Treatment with metformin also increased the abundance of probiotics *A. muciniphila* and SCFA-producing microbiota,such as *Butyrivibrio*, *B. bifidum*, and *Megasphaera*in murine and human studies[31].Here, we summarize the role of the gut microbiome in the antidiabetic effects of metformin (Figure 2).

Acarbose, an α-glucosidase inhibitor,is an oral prescription medication used to control blood glucose in T2D treatment. Acarbose has been reported to alter the composition of gut microbiota in patients with T2D, in particular increasing the abundance of *Bifidobacterium longum* and decreasing the level of lipopolysaccharides[75].Vildagliptin, a dipeptidyl peptidase 4 inhibitor, is an oral antihyperglycemic agent that enhances insulin secretion and suppresses glucagon release. Vildagliptin supplementation decreases the level of *Oscillibacter*and increases the proportion of *Lactobacillus* in HFD-induced mouse models[76]. Sitagliptin, another DPP-4 inhibitor, appears to exhibit antidiabetic functions during pregnancy in rats by reducing *Lactobacillus* spp. and increasing *Bifidobacterium* spp.[9,77]. Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, is a medication used to treat T2D. Treatment with dapagliflozin decreases the ratio of Firmicutes to Bacteroidetes and the abundance of *Oscillospira*, and increases the abundance of *A. muciniphila* in diabetic murine models[78,79].Thiazolidinediones (TZDs) are a class of oral hypoglycemic agents for the treatment of T2D[80,81].TZDsfunction through the activation of the peroxisome proliferator-activated receptor (PPAR) signaling pathway[82,83].Pioglitazone, a member of TZDs, is widely used to treat T2D. It has been reported that treatment with pioglitazone reduces the α-diversity of the gut microbiota in murine T2D models, which may be one of the mechanisms mediating its antidiabetic function[79].In our previous studies, Danshensu Bingpian Zhi, a synthetic derivative of danshensu and borneol, is a PPARγ agonistthat prevents HFD-induced atherosclerosis, obesity, and insulin resistance in mice in part by reversingintestinal microbiota dysbiosis, such as increasing the ratio of Bacteroidetes to Firmicutes, increasing the level of *Akkermansia*, and reducing the level of the harmful bacterium *Helicobacter marmotae*[84]. These results suggest that gut microbiome is a potential target of many anti-diabetic medications clinically.

Traditional Chinese medicines (TCMs) have a long history of treating diabetes, but their mechanisms are not fully understood. Several studies have suggested that TCMs have multiple therapeutic effects on diabetes, including antioxidation, suppression of inflammation, protection of intestinal mucosal barrier, and inhibition of lipotoxicity, mainly by remodeling the gut microbiota[85].Berberine, a well-known bioactive alkaloid extracted from TCM *Coptis chinensis*, has been used for the treatment of diarrhea and diabetes. Berberine is useful in diabetes management because its administration is associated with a decrease of obesity indices, such as body mass index and waist circumference[86]. Berberine maintains gut health in rats and humans with diabetes by increasing the abundance of*Bifidobacterium* and *Lactobacillus*, and decreasing the abundance of *Escherichia coli*[87,88].Gegen Qinlian Decoction can relieve T2D in clinical trials, which is associated with an increase in the level of beneficial bacteria, such as *Faecalibacterium* spp.[89].In addition, Banxia Xiexin Decoction,Huanglian Jiedu Decoction, and Qijian mixture also have beneficial effects by regulating gut microbiota[85,90,91]. These results suggest that gut microbiota is likely a new direction in elucidating the antidiabetic mechanism of TCMs.

**CONCLUSION**

Diabetes has become an urgent public health threat, and the growing trend of diabetes cases is expected to continue for the next two decades and beyond. Gut microbiome plays a critical role in health maintenance, and the dysregulation of gut microbiome can contribute to the development and progression of the disease. Here, we summarized the interaction between diabetes and the gut microbiota. Gut dysbiosis is increasingly recognized as a mechanism that induces metabolic diseases. Accumulating studies have shown that the gut microbiome is a key factor in the pathophysiology of diabetes, but research in this area is still in the early stages. Most of the studies have only shown that changes in the composition of the gut microbiota are associated with the progression of metabolic diseases. The exact causal relationship between a specific intestinal bacterium and phenotypic exposure is still not well understood. Further experiments using fecal or bacterial transplantation in germ-free mice and clinical studies are required to obtain a deeper understanding of the roles of individual bacteria in metabolic diseases. The use of metabolomics and transcriptomics to study the gut microbiome is a more effective strategy to understand the role of microbiota in the progression of host disease.

Traditionally, most pharmacological agents used for treatment of diabetes directly regulate the signaling pathways involved in glucose and insulin homeostasis. However, the gut microbiota is becoming an emerging therapeutic target for diabetes. In view of the good performance of herbal agents, particularly TCMs, in regulating gut microbiota, more consideration should be given to the use of medicinal herbs for the treatment of diabetes.

**REFERENCES**

1 **Saeedi P**, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 2019; **157**: 107843 [PMID: 31518657 DOI: 10.1016/j.diabres.2019.107843]

2 **Saeedi P**, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg EW, Unwin N, Wild SH, Williams R. Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 2020; **162**: 108086 [PMID: 32068099 DOI: 10.1016/j.diabres.2020.108086]

3 **Zheng Y**, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol* 2018; **14**: 88-98 [PMID: 29219149 DOI: 10.1038/nrendo.2017.151]

4 **Sharma S**, Tripathi P. Gut microbiome and type 2 diabetes: where we are and where to go? *J Nutr Biochem* 2019; **63**: 101-108 [PMID: 30366260 DOI: 10.1016/j.jnutbio.2018.10.003]

5 **Zhang Y**, Gu Y, Ren H, Wang S, Zhong H, Zhao X, Ma J, Gu X, Xue Y, Huang S, Yang J, Chen L, Chen G, Qu S, Liang J, Qin L, Huang Q, Peng Y, Li Q, Wang X, Kong P, Hou G, Gao M, Shi Z, Li X, Qiu Y, Zou Y, Yang H, Wang J, Xu G, Lai S, Li J, Ning G, Wang W. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). *Nat Commun* 2020; **11**: 5015 [PMID: 33024120 DOI: 10.1038/s41467-020-18414-8]

6 **Nathan DM**, Bennett PH, Crandall JP, Edelstein SL, Goldberg RB, Kahn SE, Knowler WC, Mather KJ, Mudaliar S, Orchard TJ, Temprosa M, White NH; Research Group. Does diabetes prevention translate into reduced long-term vascular complications of diabetes? *Diabetologia* 2019; **62**: 1319-1328 [PMID: 31270584 DOI: 10.1007/s00125-019-4928-8]

7 **Williams R**, Karuranga S, Malanda B, Saeedi P, Basit A, Besançon S, Bommer C, Esteghamati A, Ogurtsova K, Zhang P, Colagiuri S. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 2020; **162**: 108072 [PMID: 32061820 DOI: 10.1016/j.diabres.2020.108072]

8 **Fan Y**, Pedersen O. Gut microbiota in human metabolic health and disease. *Nat Rev Microbiol* 2021; **19**: 55-71 [PMID: 32887946 DOI: 10.1038/s41579-020-0433-9]

9 **Kyriachenko Y**, Falalyeyeva T, Korotkyi O, Molochek N, Kobyliak N. Crosstalk between gut microbiota and antidiabetic drug action. *World J Diabetes* 2019; **10**: 154-168 [PMID: 30891151 DOI: 10.4239/wjd.v10.i3.154]

10 **Ye P**, Xi Y, Huang Z, Xu P. Linking Obesity with Colorectal Cancer: Epidemiology and Mechanistic Insights. *Cancers (Basel)* 2020; **12** [PMID: 32486076 DOI: 10.3390/cancers12061408]

11 **Sircana A**, Framarin L, Leone N, Berrutti M, Castellino F, Parente R, De Michieli F, Paschetta E, Musso G. Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence? *Curr Diab Rep* 2018; **18**: 98 [PMID: 30215149 DOI: 10.1007/s11892-018-1057-6]

12 **He C**, Shan Y, Song W. Targeting gut microbiota as a possible therapy for diabetes. *Nutr Res* 2015; **35**: 361-367 [PMID: 25818484 DOI: 10.1016/j.nutres.2015.03.002]

13 **Panwar H**, Rashmi HM, Batish VK, Grover S. Probiotics as potential biotherapeutics in the management of type 2 diabetes - prospects and perspectives. *Diabetes Metab Res Rev* 2013; **29**: 103-112 [PMID: 23225499 DOI: 10.1002/dmrr.2376]

14 **Gurung M**, Li Z, You H, Rodrigues R, Jump DB, Morgun A, Shulzhenko N. Role of gut microbiota in type 2 diabetes pathophysiology. *EBioMedicine* 2020; **51**: 102590 [PMID: 31901868 DOI: 10.1016/j.ebiom.2019.11.051]

15 **Găman MA**, Epîngeac ME, Diaconu CC, Găman AM. Evaluation of oxidative stress levels in obesity and diabetes by the free oxygen radical test and free oxygen radical defence assays and correlations with anthropometric and laboratory parameters. *World J Diabetes* 2020; **11**: 193-201 [PMID: 32477455 DOI: 10.4239/wjd.v11.i5.193]

16 **Sohouli MH**, Fatahi S, Sharifi-Zahabi E, Santos HO, Tripathi N, Lari A, Pourrajab B, Kord-Varkaneh H, Găman MA, Shidfar F. The Impact of Low Advanced Glycation End Products Diet on Metabolic Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Adv Nutr* 2021; **12**: 766-776 [PMID: 33253361 DOI: 10.1093/advances/nmaa150]

17 **Pourrajab B**, Fatahi S, Sohouli MH, Găman MA, Shidfar F. The effects of probiotic/synbiotic supplementation compared to placebo on biomarkers of oxidative stress in adults: a systematic review and meta-analysis of randomized controlled trials. *Crit Rev Food Sci Nutr* 2020: 1-18 [PMID: 33016089 DOI: 10.1080/10408398.2020.1821166]

18 **Brunkwall L**, Orho-Melander M. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. *Diabetologia* 2017; **60**: 943-951 [PMID: 28434033 DOI: 10.1007/s00125-017-4278-3]

19 **Everard A**, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A* 2013; **110**: 9066-9071 [PMID: 23671105 DOI: 10.1073/pnas.1219451110]

20 **Caesar R**, Tremaroli V, Kovatcheva-Datchary P, Cani PD, Bäckhed F. Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling. *Cell Metab* 2015; **22**: 658-668 [PMID: 26321659 DOI: 10.1016/j.cmet.2015.07.026]

21 **Dao MC**, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD, Levenez F, Chilloux J, Hoyles L; MICRO-Obes Consortium, Dumas ME, Rizkalla SW, Doré J, Cani PD, Clément K. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. *Gut* 2016; **65**: 426-436 [PMID: 26100928 DOI: 10.1136/gutjnl-2014-308778]

22 **Derrien M**, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. *Microb Pathog* 2017; **106**: 171-181 [PMID: 26875998 DOI: 10.1016/j.micpath.2016.02.005]

23 **Plovier H**, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KC, Aalvink S, Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani PD. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat Med* 2017; **23**: 107-113 [PMID: 27892954 DOI: 10.1038/nm.4236]

24 **Depommier C**, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. *Nat Med* 2019; **25**: 1096-1103 [PMID: 31263284 DOI: 10.1038/s41591-019-0495-2]

25 **Xu P**, Wang J, Hong F, Wang S, Jin X, Xue T, Jia L, Zhai Y. Melatonin prevents obesity through modulation of gut microbiota in mice. *J Pineal Res* 2017; **62** [PMID: 28199741 DOI: 10.1111/jpi.12399]

26 **Zhang X**, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y, Ji L. Human gut microbiota changes reveal the progression of glucose intolerance. *PLoS One* 2013; **8**: e71108 [PMID: 24013136 DOI: 10.1371/journal.pone.0071108]

27 **Yamaguchi Y**, Adachi K, Sugiyama T, Shimozato A, Ebi M, Ogasawara N, Funaki Y, Goto C, Sasaki M, Kasugai K. Association of Intestinal Microbiota with Metabolic Markers and Dietary Habits in Patients with Type 2 Diabetes. *Digestion* 2016; **94**: 66-72 [PMID: 27504897 DOI: 10.1159/000447690]

28 **Munukka E**, Wiklund P, Pekkala S, Völgyi E, Xu L, Cheng S, Lyytikäinen A, Marjomäki V, Alen M, Vaahtovuo J, Keinänen-Kiukaanniemi S, Cheng S. Women with and without metabolic disorder differ in their gut microbiota composition. *Obesity (Silver Spring)* 2012; **20**: 1082-1087 [PMID: 22293842 DOI: 10.1038/oby.2012.8]

29 **Lippert K**, Kedenko L, Antonielli L, Kedenko I, Gemeier C, Leitner M, Kautzky-Willer A, Paulweber B, Hackl E. Gut microbiota dysbiosis associated with glucose metabolism disorders and the metabolic syndrome in older adults. *Benef Microbes* 2017; **8**: 545-556 [PMID: 28701081 DOI: 10.3920/BM2016.0184]

30 **Candela M**, Biagi E, Soverini M, Consolandi C, Quercia S, Severgnini M, Peano C, Turroni S, Rampelli S, Pozzilli P, Pianesi M, Fallucca F, Brigidi P. Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic Ma-Pi 2 diet. *Br J Nutr* 2016; **116**: 80-93 [PMID: 27151248 DOI: 10.1017/S0007114516001045]

31 **Wu H**, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernàndez-Real JM, Bäckhed F. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. *Nat Med* 2017; **23**: 850-858 [PMID: 28530702 DOI: 10.1038/nm.4345]

32 **Murphy R**, Tsai P, Jüllig M, Liu A, Plank L, Booth M. Differential Changes in Gut Microbiota After Gastric Bypass and Sleeve Gastrectomy Bariatric Surgery Vary According to Diabetes Remission. *Obes Surg* 2017; **27**: 917-925 [PMID: 27738970 DOI: 10.1007/s11695-016-2399-2]

33 **Sun L**, Xie C, Wang G, Wu Y, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, Zhang S, Yun C, Lian G, Zhang X, Zhang H, Bisson WH, Shi J, Gao X, Ge P, Liu C, Krausz KW, Nichols RG, Cai J, Rimal B, Patterson AD, Wang X, Gonzalez FJ, Jiang C. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. *Nat Med* 2018; **24**: 1919-1929 [PMID: 30397356 DOI: 10.1038/s41591-018-0222-4]

34 **Gauffin Cano P**, Santacruz A, Moya Á, Sanz Y. Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with high-fat-diet induced obesity. *PLoS One* 2012; **7**: e41079 [PMID: 22844426 DOI: 10.1371/journal.pone.0041079]

35 **Yang JY**, Lee YS, Kim Y, Lee SH, Ryu S, Fukuda S, Hase K, Yang CS, Lim HS, Kim MS, Kim HM, Ahn SH, Kwon BE, Ko HJ, Kweon MN. Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice. *Mucosal Immunol* 2017; **10**: 104-116 [PMID: 27118489 DOI: 10.1038/mi.2016.42]

36 **Manome A**, Abiko Y, Kawashima J, Washio J, Fukumoto S, Takahashi N. Acidogenic Potential of Oral *Bifidobacterium* and Its High Fluoride Tolerance. *Front Microbiol* 2019; **10**: 1099 [PMID: 31156604 DOI: 10.3389/fmicb.2019.01099]

37 **Wang J**, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, van-Hylckama Vlieg JE, Strissel K, Zhao L, Obin M, Shen J. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. *ISME J* 2015; **9**: 1-15 [PMID: 24936764 DOI: 10.1038/ismej.2014.99]

38 **Le TK**, Hosaka T, Nguyen TT, Kassu A, Dang TO, Tran HB, Pham TP, Tran QB, Le TH, Pham XD. Bifidobacterium species lower serum glucose, increase expressions of insulin signaling proteins, and improve adipokine profile in diabetic mice. *Biomed Res* 2015; **36**: 63-70 [PMID: 25749152 DOI: 10.2220/biomedres.36.63]

39 **Aoki R**, Kamikado K, Suda W, Takii H, Mikami Y, Suganuma N, Hattori M, Koga Y. A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. *Sci Rep* 2017; **7**: 43522 [PMID: 28252037 DOI: 10.1038/srep43522]

40 **Zhang JL,** Wang SB, Zeng Z, Qin YX, Shen Q, Li PL. Anti-diabetic effects of Bifidobacterium animalis 01 through improving hepatic insulin sensitivity in type 2 diabetic rat model. *J Funct Foods* 2020; **67**: 103843 [DOI: 10.1016/j.jff.2020.103843]

41 **Karlsson FH**, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, Nielsen J, Bäckhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature* 2013; **498**: 99-103 [PMID: 23719380 DOI: 10.1038/nature12198]

42 **Graessler J**, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T, Bornstein SR. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. *Pharmacogenomics J* 2013; **13**: 514-522 [PMID: 23032991 DOI: 10.1038/tpj.2012.43]

43 **Forslund K**, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Pedersen HK, Arumugam M, Kristiansen K, Voigt AY, Vestergaard H, Hercog R, Costea PI, Kultima JR, Li J, Jørgensen T, Levenez F, Dore J; MetaHIT consortium, Nielsen HB, Brunak S, Raes J, Hansen T, Wang J, Ehrlich SD, Bork P, Pedersen O. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature* 2015; **528**: 262-266 [PMID: 26633628 DOI: 10.1038/nature15766]

44 **Dang F**, Jiang Y, Pan R, Zhou Y, Wu S, Wang R, Zhuang K, Zhang W, Li T, Man C. Administration of Lactobacillus paracasei ameliorates type 2 diabetes in mice. *Food Funct* 2018; **9**: 3630-3639 [PMID: 29961787 DOI: 10.1039/c8fo00081f]

45 **Ejtahed HS**, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. *Nutrition* 2012; **28**: 539-543 [PMID: 22129852 DOI: 10.1016/j.nut.2011.08.013]

46 **Fåk F**, Bäckhed F. Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/- mice. *PLoS One* 2012; **7**: e46837 [PMID: 23056479 DOI: 10.1371/journal.pone.0046837]

47 **Lee E**, Jung SR, Lee SY, Lee NK, Paik HD, Lim SI. *Lactobacillus plantarum* Strain Ln4 Attenuates Diet-Induced Obesity, Insulin Resistance, and Changes in Hepatic mRNA Levels Associated with Glucose and Lipid Metabolism. *Nutrients* 2018; **10** [PMID: 29783731 DOI: 10.3390/nu10050643]

48 **Lim SM**, Jeong JJ, Woo KH, Han MJ, Kim DH. Lactobacillus sakei OK67 ameliorates high-fat diet-induced blood glucose intolerance and obesity in mice by inhibiting gut microbiota lipopolysaccharide production and inducing colon tight junction protein expression. *Nutr Res* 2016; **36**: 337-348 [PMID: 27001279 DOI: 10.1016/j.nutres.2015.12.001]

49 **Martinic A**, Barouei J, Bendiks Z, Mishchuk D, Heeney DD, Martin R, Marco ML, Slupsky CM. Supplementation of Lactobacillus plantarum Improves Markers of Metabolic Dysfunction Induced by a High Fat Diet. *J Proteome Res* 2018; **17**: 2790-2802 [PMID: 29931981 DOI: 10.1021/acs.jproteome.8b00282]

50 **Naito E**, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, Matsuzaki T, Miyazaki K, Ishikawa F. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. *J Appl Microbiol* 2011; **110**: 650-657 [PMID: 21281408 DOI: 10.1111/j.1365-2672.2010.04922.x]

51 **Park DY**, Ahn YT, Park SH, Huh CS, Yoo SR, Yu R, Sung MK, McGregor RA, Choi MS. Supplementation of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 in diet-induced obese mice is associated with gut microbial changes and reduction in obesity. *PLoS One* 2013; **8**: e59470 [PMID: 23555678 DOI: 10.1371/journal.pone.0059470]

52 **Park KY**, Kim B, Hyun CK. Lactobacillus rhamnosus GG improves glucose tolerance through alleviating ER stress and suppressing macrophage activation in db/db mice. *J Clin Biochem Nutr* 2015; **56**: 240-246 [PMID: 26060355 DOI: 10.3164/jcbn.14-116]

53 **Sabico S**, Al-Mashharawi A, Al-Daghri NM, Yakout S, Alnaami AM, Alokail MS, McTernan PG. Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial. *J Transl Med* 2017; **15**: 249 [PMID: 29228964 DOI: 10.1186/s12967-017-1354-x]

54 **Yun SI**, Park HO, Kang JH. Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. *J Appl Microbiol* 2009; **107**: 1681-1686 [PMID: 19457033 DOI: 10.1111/j.1365-2672.2009.04350.x]

55 **Li KK,** Tian PJ, Wang SD, Lei P, Qu L, Huang JP, Shan YJ, Li BL. Targeting gut microbiota: Lactobacillus alleviated type 2 diabetes via inhibiting LPS secretion and activating GPR43 pathway. *J Funct Foods* 2017; **38**: 561-570 [DOI: 10.1016/j.jff.2017.09.049]

56 **Li WZ**, Stirling K, Yang JJ, Zhang L. Gut microbiota and diabetes: From correlation to causality and mechanism. *World J Diabetes* 2020; **11**: 293-308 [PMID: 32843932 DOI: 10.4239/wjd.v11.i7.293]

57 **Ponzo V**, Fedele D, Goitre I, Leone F, Lezo A, Monzeglio C, Finocchiaro C, Ghigo E, Bo S. Diet-Gut Microbiota Interactions and Gestational Diabetes Mellitus (GDM). *Nutrients* 2019; **11** [PMID: 30717458 DOI: 10.3390/nu11020330]

58 **Lazar V**, Ditu LM, Pircalabioru GG, Picu A, Petcu L, Cucu N, Chifiriuc MC. Gut Microbiota, Host Organism, and Diet Trialogue in Diabetes and Obesity. *Front Nutr* 2019; **6**: 21 [PMID: 30931309 DOI: 10.3389/fnut.2019.00021]

59 **Serino M**, Luche E, Gres S, Baylac A, Bergé M, Cenac C, Waget A, Klopp P, Iacovoni J, Klopp C, Mariette J, Bouchez O, Lluch J, Ouarné F, Monsan P, Valet P, Roques C, Amar J, Bouloumié A, Théodorou V, Burcelin R. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. *Gut* 2012; **61**: 543-553 [PMID: 22110050 DOI: 10.1136/gutjnl-2011-301012]

60 **Fallucca F**, Fontana L, Fallucca S, Pianesi M. Gut microbiota and Ma-Pi 2 macrobiotic diet in the treatment of type 2 diabetes. *World J Diabetes* 2015; **6**: 403-411 [PMID: 25897351 DOI: 10.4239/wjd.v6.i3.403]

61 **Ganesan K**, Chung SK, Vanamala J, Xu B. Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes. *Int J Mol Sci* 2018; **19**: 3720 [PMID: 30467295 DOI: 10.3390/ijms19123720]

62 **Wu WC**, Inui A, Chen CY. Weight loss induced by whole grain-rich diet is through a gut microbiota-independent mechanism. *World J Diabetes* 2020; **11**: 26-32 [PMID: 32064033 DOI: 10.4239/wjd.v11.i2.26]

63 **Myhrstad MCW**, Tunsjø H, Charnock C, Telle-Hansen VH. Dietary Fiber, Gut Microbiota, and Metabolic Regulation-Current Status in Human Randomized Trials. *Nutrients* 2020; **12**: 859 [PMID: 32210176 DOI: 10.3390/nu12030859]

64 **den Besten G**, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J Lipid Res* 2013; **54**: 2325-2340 [PMID: 23821742 DOI: 10.1194/jlr.R036012]

65 **Louis P**, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. *Nat Rev Microbiol* 2014; **12**: 661-672 [PMID: 25198138 DOI: 10.1038/nrmicro3344]

66 **Feng W**, Ao H, Peng C. Gut Microbiota, Short-Chain Fatty Acids, and Herbal Medicines. *Front Pharmacol* 2018; **9**: 1354 [PMID: 30532706 DOI: 10.3389/fphar.2018.01354]

67 **Reichardt N**, Duncan SH, Young P, Belenguer A, McWilliam Leitch C, Scott KP, Flint HJ, Louis P. Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. *ISME J* 2014; **8**: 1323-1335 [PMID: 24553467 DOI: 10.1038/ismej.2014.14]

68 **Parada Venegas D**, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, Harmsen HJM, Faber KN, Hermoso MA. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. *Front Immunol* 2019; **10**: 277 [PMID: 30915065 DOI: 10.3389/fimmu.2019.00277]

69 **Puddu A**, Sanguineti R, Montecucco F, Viviani GL. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. *Mediators Inflamm* 2014; **2014**: 162021 [PMID: 25214711 DOI: 10.1155/2014/162021]

70 **Xu P**, Hong F, Wang J, Cong Y, Dai S, Wang S, Wang J, Jin X, Wang F, Liu J, Zhai Y. Microbiome Remodeling via the Montmorillonite Adsorption-Excretion Axis Prevents Obesity-related Metabolic Disorders. *EBioMedicine* 2017; **16**: 251-261 [PMID: 28126594 DOI: 10.1016/j.ebiom.2017.01.019]

71 **Xu P**, Dai S, Wang J, Zhang J, Liu J, Wang F, Zhai Y. Preventive obesity agent montmorillonite adsorbs dietary lipids and enhances lipid excretion from the digestive tract. *Sci Rep* 2016; **6**: 19659 [PMID: 26891902 DOI: 10.1038/srep19659]

72 **Leeming ER**, Johnson AJ, Spector TD, Le Roy CI. Effect of Diet on the Gut Microbiota: Rethinking Intervention Duration. *Nutrients* 2019; **11**: 2862 [PMID: 31766592 DOI: 10.3390/nu11122862]

73 **Guo GL**, Xie W. Metformin action through the microbiome and bile acids. *Nat Med* 2018; **24**: 1789-1790 [PMID: 30523325 DOI: 10.1038/s41591-018-0273-6]

74 **Hardie DG**, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. *Nat Rev Mol Cell Biol* 2012; **13**: 251-262 [PMID: 22436748 DOI: 10.1038/nrm3311]

75 **Su B**, Liu H, Li J, Sunli Y, Liu B, Liu D, Zhang P, Meng X. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. *J Diabetes* 2015; **7**: 729-739 [PMID: 25327485 DOI: 10.1111/1753-0407.12232]

76 **Olivares M**, Neyrinck AM, Pötgens SA, Beaumont M, Salazar N, Cani PD, Bindels LB, Delzenne NM. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice. *Diabetologia* 2018; **61**: 1838-1848 [PMID: 29797022 DOI: 10.1007/s00125-018-4647-6]

77 **Paul HA**, Bomhof MR, Vogel HJ, Reimer RA. Diet-induced changes in maternal gut microbiota and metabolomic profiles influence programming of offspring obesity risk in rats. *Sci Rep* 2016; **6**: 20683 [PMID: 26868870 DOI: 10.1038/srep20683]

78 **Lee DM**, Battson ML, Jarrell DK, Hou S, Ecton KE, Weir TL, Gentile CL. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. *Cardiovasc Diabetol* 2018; **17**: 62 [PMID: 29703207 DOI: 10.1186/s12933-018-0708-x]

79 **Yang M**, Shi FH, Liu W, Zhang MC, Feng RL, Qian C, Liu W, Ma J. Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model. *Front Endocrinol (Lausanne)* 2020; **11**: 635 [PMID: 33312157 DOI: 10.3389/fendo.2020.00635]

80 **Hong F**, Xu P, Zhai Y. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. *Int J Mol Sci* 2018; **19**: 2189 [PMID: 30060458 DOI: 10.3390/ijms19082189]

81 **Xu P**, Zhai Y, Wang J. The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis. *Int J Mol Sci* 2018; **19**: 1260 [PMID: 29690611 DOI: 10.3390/ijms19041260]

82 **Xi Y**, Zhang Y, Zhu S, Luo Y, Xu P, Huang Z. PPAR-Mediated Toxicology and Applied Pharmacology. *Cells* 2020; **9**: 352 [PMID: 32028670 DOI: 10.3390/cells9020352]

83 **Hong F**, Pan S, Guo Y, Xu P, Zhai Y. PPARs as Nuclear Receptors for Nutrient and Energy Metabolism. *Molecules* 2019; **24**: 2545 [PMID: 31336903 DOI: 10.3390/molecules24142545]

84 **Xu P**, Hong F, Wang J, Wang J, Zhao X, Wang S, Xue T, Xu J, Zheng X, Zhai Y. DBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis. *Biochim Biophys Acta Gen Subj* 2017; **1861**: 2690-2701 [PMID: 28736228 DOI: 10.1016/j.bbagen.2017.07.013]

85 **Zhang B**, Yue R, Chen Y, Yang M, Huang X, Shui J, Peng Y, Chin J. Gut Microbiota, a Potential New Target for Chinese Herbal Medicines in Treating Diabetes Mellitus. *Evid Based Complement Alternat Med* 2019; **2019**: 2634898 [PMID: 30906411 DOI: 10.1155/2019/2634898]

86 **Xiong P**, Niu L, Talaei S, Kord-Varkaneh H, Clark CCT, Găman MA, Rahmani J, Dorosti M, Mousavi SM, Zarezadeh M, Taghizade-Bilondi H, Zhang J. The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials. *Complement Ther Clin Pract* 2020; **39**: 101113 [PMID: 32379652 DOI: 10.1016/j.ctcp.2020.101113]

87 **Liu D**, Zhang Y, Liu Y, Hou L, Li S, Tian H, Zhao T. Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway. *Exp Clin Endocrinol Diabetes* 2018; **126**: 513-520 [PMID: 29365334 DOI: 10.1055/s-0043-125066]

88 **Zhang X**, Zhao Y, Xu J, Xue Z, Zhang M, Pang X, Zhang X, Zhao L. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. *Sci Rep* 2015; **5**: 14405 [PMID: 26396057 DOI: 10.1038/srep14405]

89 **Xu J**, Lian F, Zhao L, Zhao Y, Chen X, Zhang X, Guo Y, Zhang C, Zhou Q, Xue Z, Pang X, Zhao L, Tong X. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. *ISME J* 2015; **9**: 552-562 [PMID: 25279787 DOI: 10.1038/ismej.2014.177]

90 **Gao K**, Yang R, Zhang J, Wang Z, Jia C, Zhang F, Li S, Wang J, Murtaza G, Xie H, Zhao H, Wang W, Chen J. Effects of Qijian mixture on type 2 diabetes assessed by metabonomics, gut microbiota and network pharmacology. *Pharmacol Res* 2018; **130**: 93-109 [PMID: 29391233 DOI: 10.1016/j.phrs.2018.01.011]

91 **Chen M**, Liao Z, Lu B, Wang M, Lin L, Zhang S, Li Y, Liu D, Liao Q, Xie Z. Huang-Lian-Jie-Du-Decoction Ameliorates Hyperglycemia and Insulin Resistant in Association With Gut Microbiota Modulation. *Front Microbiol* 2018; **9**: 2380 [PMID: 30349514 DOI: 10.3389/fmicb.2018.02380]

**Footnotes**

**Conflict-of-interest statement:** Authors have nothing to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 24, 2021

**First decision:** April 6, 2021

**Article in press:**

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Gaman MA, Lee YL **S-Editor:** Liu M **L-Editor:** Kerr C **P-Editor:**

**Figure Legends**



**Figure 1 Millions of diabetes cases in 2019 and projections to 2030 and 2045, with projected percentage changes.** Data are from the International Diabetes Federation Diabetes Atlas (9th edition 2019).



**Figure 2 The schematic mechanisms of metformin act through the gut microbiome and the related beneficial effects on diabetes.** AMPK: AMP-activated protein kinase; FXR: farnesoid X receptor; GUDCA: glycoursodeoxycholic acid; SCFAs: short-chain fatty acids.